论文部分内容阅读
继临床应用的第二代H_2受体拮抗剂甲氰脒胍于1975年问世之后,1976年含呋喃环衍生物的雷尼替丁问世,随之在我国制成上市。目前,日有效剂量仅为甲氰脒胍的1/20,雷尼替丁的1/4,血药浓度持续时间长,副作用远比甲氰脒胍小,含噻唑衍生物的H_2桔抗剂法莫替丁Famatidine)又已在国外行销。此药自1984年下半年以来,我国已在合成试制中取得成功。预料不久即可投产问世。在这一期里,作了有关介绍,为读者传递信息。
Following the clinical application of the second generation of H 2 receptor antagonist cimetidine guanidine came out in 1975, ranitidine containing furan ring derivatives 1976, followed by the listing in China. At present, the daily effective dose is only 1/20 of cimetidine, 1/4 of ranitidine, the plasma concentration lasts longer and the side effects are smaller than that of cidamidoguanidine. The H 2 orange antagonist containing thiazole derivatives Famotidine Famatidine) has been marketed abroad. Since the second half of 1984, our country has succeeded in the synthesis trial. Expected to come into operation shortly after production. In this period, made a presentation about the message for the reader.